lead iPSC-derived CAR T-cell therapy (Takeda)

N/A

Report date: 2025/01/26 19:10:16

Base Information

Drug Namelead iPSC-derived CAR T-cell therapy (Takeda)

Drug Alias Namelead iCART (Center for iPS Cell Research and Application (CiRA) at Kyoto University/Takeda)lead iPSC-derived CAR T-cell therapy (Kyoto University/Takeda/T-CiRA)lead iCART (Takeda)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunostimulantsT lymphocytes stimulants

TargetsUpdating

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesKyoto University

China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceutical Co Ltd

Inactive CompaniesKyoto University

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A